The estimated Net Worth of Timothy Michael Wright is at least $5.65 Million dollars as of 25 July 2017. Timothy Wright owns over 274,725 units of Schrodinger stock worth over $5,653,841 and over the last 8 years he sold SDGR stock worth over $0. In addition, he makes $0 as Independent Director at Schrodinger.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Timothy Wright SDGR stock SEC Form 4 insiders trading
Timothy has made over 1 trades of the Schrodinger stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 274,725 units of SDGR stock worth $250,000 on 25 July 2017.
The largest trade he's ever made was buying 274,725 units of Schrodinger stock on 25 July 2017 worth over $250,000. On average, Timothy trades about 30,525 units every 0 days since 2016. As of 25 July 2017 he still owns at least 274,725 units of Schrodinger stock.
You can see the complete history of Timothy Wright stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Wright biography
Dr. Timothy Wright M.D. serves as Independent Director of the Company. Dr. Wright has served as general partner at Time BioVentures, a life sciences venture capital firm, since April 2019. Prior to that, Dr. Wright served as chief research and development officer at Regulus Therapeutics, Inc. or Regulus, a biopharmaceutical company, from September 2016 to March 2019. Prior to joining Regulus, Dr. Wright served as executive vice president, translational sciences at the California Institute for Biomedical Research, a non-profit organization, from February 2015 to August 2016. Prior to that, Dr. Wright held positions of increasing responsibility at Novartis Pharmaceuticals, a multinational pharmaceutical company, from April 2004 to January 2015, including deputy head of translational research, global head of translational medicine, global head of translational sciences and global head of pharma development. Dr. Wright currently serves as a scientific advisor to the Bill and Melinda Gates Foundation and to the Leonard Schaeffer Center for Health Policy and Economics at University of Southern California. Dr. Wright received a B.A. in Biology from the University of Delaware and an M.D. from the Johns Hopkins University School of Medicine where he also completed postdoctoral training. Wright’s business experience and knowledge of the life sciences industry in which we operate qualifies him to serve on our board of directors.
How old is Timothy Wright?
Timothy Wright is 64, he's been the Independent Director of Schrodinger since 2015. There are 2 older and 20 younger executives at Schrodinger. The oldest executive at Schrodinger, Inc. is Dr. Richard A. Friesner, 68, who is the Co-Founder, Scientific Advisory Chairman and Director.
What's Timothy Wright's mailing address?
Timothy's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK, NY, 10036.
Insiders trading at Schrodinger
Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ..., and Michael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.
What does Schrodinger do?
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
What does Schrodinger's logo look like?
Complete history of Timothy Wright stock trades at Regulus Therapeutics Inc and Schrodinger
Schrodinger executives and stock owners
Schrodinger executives and other stock owners filed with the SEC include:
-
Dr. Ramy Farid Ph.D.,
CEO, Pres & Director -
Yvonne Tran Esq.,
Exec. VP, Chief Legal Officer & Sec. -
Dr. Karen Akinsanya Ph.D.,
Exec. VP, Chief Biomedical Scientist and Head of Discovery R&D -
Ramy Farid,
President, Chief Executive Officer, Director -
Cony D cruz,
Executive Vice President - Chief Business Officer -
Yvonne Tran,
Executive Vice President, Chief Legal Officer -
Dr. Richard A. Friesner,
Co-Founder, Scientific Advisory Chairman and Director -
Richard Friesner,
Independent Director -
Nancy Thornberry,
Independent Director -
Gary Sender,
Independent Director -
Rosana Kapeller-Libermann,
Independent Director -
Timothy Wright,
Independent Director -
Shane Brauner,
Senior Vice President, Chief Information Officer -
Kenneth Lorton,
Senior Vice President, Chief Technology Officer -
Karen Akinsanya,
Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D -
Robert Abel,
Executive Vice President - science -
Jorg Weiser,
Executive Vice President, Managing Director -
Jennifer Daniel,
Chief Human Resource Officer, Senior Vice President -
Joel Lebowitz,
Executive Vice President, Chief Financial Officer -
Michael Lynton,
Independent Chairman of the Board of Directors -
Michelle Byington,
VP of HR -
Jennifer Mayer Daniel,
Sr. VP & Chief HR Officer -
Jaren Irene Madden,
Sr. VP of Investor Relations & Corp. Communications -
Shane Brauner,
Exec. VP & Chief Information Officer -
Kenneth Patrick Lorton,
Exec. VP & CTO -
Prof. William Goddard III,
Co-Founder & Scientific Advisor -
Charles Ardai,
10% owner -
Geoffrey Craig Porges,
EVP & CFO -
David E Shaw,
10% owner -
Gary L Ginsberg,
Director -
Jeffrey Chodakewitz,
Director -
& Melinda Gates Foundation ...,
10% owner -
David E Schrodinger Equity ...,
-
James E Deerfield Mgmt Iv, ...,
-
Jenny Herman,
SVP & Controller -
Arun Oberoi,
Director -
Margaret Dugan,
Chief Medical Officer